Johnson & Johnson Innovation, an organisation from Janssen’s parent company, announced the opening of the Asia Pacific Innovation Centre on 29 October, located in Shanghai with satellites in Singapore, Australia and Japan.
Following the opening of innovation centres in London, California and Boston
“We are excited to launch the Asia Pacific Innovation Center which builds on the momentum of our Centres in London, California and Boston. Our goal is to collaborate with the best minds in the region to advance new technologies and deliver transformative solutions for the people of China and Asia Pacific at large, and throughout the world,” said Paul Stoffels, MD., Johnson & Johnson Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals.
Johnson & Johnson Innovation and the Asia Pacific Innovation Centre (APIC) will expand on the strong relationships and innovation network already established in the region and build on the country-level strategies to advance the most promising science. With local science and technology experts and deal-making capabilities, the Centre will identify and develop promising early-stage opportunities for Janssen’s pharmaceutical development as well as for Johnson & Johnson’s other areas of focus: Medical Devices and Diagnostics and Consumer healthcare products. Janssen’s Innovation and scientific development efforts are embedded in the wider Johnson & Johnson research capabilities. More information can be found on www.jnjinnovation.com.
Headquartered in Shanghai, the APIC has satellites in Singapore, Japan (Tokyo), and Australia/New Zealand (Sydney) to provide one stop access for entrepreneurs and innovators across China, Australia, New Zealand, Korea, Japan, Singapore, and South-East Asia, including India.
To read the official press release, please click here.